Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Simons SH, Van Dijk M, Anand KS, Roofthooft D, Van Lingen RA, Tibboel D. Do we still hurt newborn babies?: A prospective study of procedural pain and analgesia in neonates. Arch. Pediatr. Adolesc. Med. 157(11), 1058–1064 (2003).
  MedlineGoogle Scholar
• 2 Anand KJS, Hickey PR. Pain and its effects in the human neonate and fetus. N. Engl. J. Med. 317(21), 1321–1329 (1987).
  Medline CASGoogle Scholar
• 3 De Graaf J, Van Lingen RA, Simons SHP et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children’s functioning: Five-year follow-up of a randomized controlled trial. Pain 152(6), 1391–1397 (2011).
  Medline CASGoogle Scholar
• 4 De Graaf J, Van Lingen RA, Valkenburg AJ et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? Pain 154(3), 449–458 (2013).
  Medline CASGoogle Scholar
• 5 Bellù R, De Waal KA, Zanini R. Opioids for neonates receiving mechanical ventilation. Cochrane Database Syst.Rev. 23(1), CD004212 (2008). • Meta-analysis: morphine routine use during ventilation in newborns not recommended due to lack of effect on mortality, duration ventilation and neurodvelopmental outcomes.
  Google Scholar
• 6 Simons SH, Van Dijk M, Van Lingen RA et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA 290(18), 2419–2427 (2003).
  Medline CASGoogle Scholar
• 7 Anand KJS, Hall RW, Desai N et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet 363(9422), 1673–1682 (2004).•• Large randomized controlled trial (n = 898) of placebo versus morphine in newborns on mechanical ventilation.
  Medline CASGoogle Scholar
• 8 Ceelie I, De Wildt SN, Van Dijk M et al. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. JAMA 309(2), 149–154 (2013).
  Medline CASGoogle Scholar
• 9 Van Dijk M, Bouwmeester NJ, Duivenvoorden HJ et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0–3-year-old infants; a double-blind randomized controlled trial. Pain 98(3), 305–313 (2002).
  Medline CASGoogle Scholar
• 10 Sadhasivam S, Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics 13(15), 1719–1740 (2012).
  CASGoogle Scholar
• 11 Hajj A, Khabbaz L, Laplanche J-L, Peoc’h K. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics 14(5), 575–585 (2013).• Special report recently published on pharmacogenetics of opioids.
  CASGoogle Scholar
• 12 Mamie C, Rebsamen MC, Morris MA, Morabia A. First evidence of a polygenic susceptibility to pain in a pediatric cohort. Anesthes. Analg. 116(1), 170–177 (2013).
  Medline CASGoogle Scholar
• 13 Wachman EM, Hayes MJ, Brown MS et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 309(17), 1821–1827 (2013).•• First study in newborns showing relationship between OPRM1 and COMT SNPs with withdrawal in neonates after in utero opioid exposure.
  Medline CASGoogle Scholar
• 14 Kasai S, Ikeda K. Pharmacogenomics of the human µ-opioid receptor. Pharmacogenomics 12(9), 1305–1320 (2011).
  CASGoogle Scholar
• 15 Mura E, Govoni S, Racchi M et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J. Pain Res. 6, 331–353 (2013).
  Medline CASGoogle Scholar
• 16 National Center for Biotechnology Information (NCBI). SNP database. HapMap CEU. http://hapmap.ncbi.nlm.nih.gov/downloads/index.html.en
  Google Scholar
• 17 Kolesnikov Y, Gabovits B, Levin A et al. Chronic pain after lower abdominal surgery: do catechol-O-methyl transferase/opioid receptor mu-1 polymorphisms contribute? Molecular Pain 9(1), 19 (2013).
  MedlineGoogle Scholar
• 18 Klepstad P, Rakvåg TT, Kaasa S et al. The 118 A > G polymorphism in the human µ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232–1239 (2004).
  Medline CASGoogle Scholar
• 19 Chou WY, Yang LC, Lu HF et al. Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7), 787–792 (2006).
  Medline CASGoogle Scholar
• 20 Reyes-Gibby CC, Shete S, Rakvåg T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1–2), 25–30 (2007).•• First study in adults showing association between opioid response and joint effects of OPRM1 and COMT.
  Medline CASGoogle Scholar
• 21 Hayashida M, Nagashima M, Satoh Y et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11), 1605–1616 (2008).
  CASGoogle Scholar
• 22 Tan E-C, Lim E, Teo Y-Y, Lim Y, Law H-Y, Sia A. Ethnicity and OPRM1 variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol. Pain 5(1), 32 (2009).
  MedlineGoogle Scholar
• 23 Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105(2), 334–337 (2006).
  Medline CASGoogle Scholar
• 24 Sia AT, Lim Y, Lim EC et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3), 520–526 (2008).
  Medline CASGoogle Scholar
• 25 Sia AT, Lim Y, Lim ECP et al. Influence of Mu-opioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. J. Pain 14(10), 1045–1052 (2013).
  Medline CASGoogle Scholar
• 26 Cargnin S, Magnani F, Viana M et al. An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans. J. Pain 14(10), 1097–1106 (2013).
  Medline CASGoogle Scholar
• 27 Kowarik MC, Einhäuser J, Jochim B et al. Impact of the COMT Val108/158Met polymorphism on the mu-opioid receptor system in the human brain: mu-opioid receptor, met-enkephalin and beta-endorphin expression. Neurosci. Lett. 506(2), 214–219 (2012).
  Medline CASGoogle Scholar
• 28 Lotta T VJ, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34(13), 4202–4210 (1995).
  Medline CASGoogle Scholar
• 29 Zubieta J-K, Heitzeg MM, Smith YR et al. COMT val158met genotype affects µ-opioid neurotransmitter responses to a pain stressor. Science 299(5610), 1240–1243 (2003).
  Medline CASGoogle Scholar
• 30 Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and μ-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth. Analg. 112(2), 448–453 (2011).
  Medline CASGoogle Scholar
• 31 Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Ann. Rev. Physiol. 69(1), 511–534 (2007).
  Medline CASGoogle Scholar
• 32 Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin F-T. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286(5449), 2495–2498 (1999).
  Medline CASGoogle Scholar
• 33 Ross JR, Rutter D, Welsh K et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. 5(5), 324–336 (2005).
  Google Scholar
• 34 Walter C, Doehring A, Oertel BG, Lötsch J. µ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics 14(15), 1915–1925 (2013).•• Comprehensive review recently published on OPRM1 118A>G genetic variation.
  CASGoogle Scholar
• 35 Abu-Saad H. Assessing children’s responses to pain. Pain 19(2), 163–171 (1984).
  Medline CASGoogle Scholar
• 36 Huskisson EC. Measurement of pain. Lancet 2(7889), 1127–1131 (1974).
  Medline CASGoogle Scholar
• 37 Gregori M, Garbin G, Gregori S et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur. J. Clin. Pharmacol. 69(9), 1651–1658 (2013).
  MedlineGoogle Scholar
• 38 Klepstad P, Rakvag TT, Kaasa S et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232–1239 (2004).
  Medline CASGoogle Scholar
• 39 Matsuoka H, Arao T, Makimura C et al. Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. Oncol .Rep. 27(5), 1393–1399 (2012).
  Medline CASGoogle Scholar
• 40 Rakvåg TT, Klepstad P, Baar C et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116(1–2), 73–78 (2005).
  Medline CASGoogle Scholar
• 41 Chen LK, Chen SS, Huang CH et al. Polymorphism of μ-opioid receptor gene (OPRM1:c.118A>G) might not protect against or enhance morphine-induced nausea or vomiting. Pain Res. Treat. 2013, 259306 (2013).
  MedlineGoogle Scholar
• 42 Coulbault L, Beaussier M, Verstuyft C et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol .Ther. 79(4), 316–324 (2006).
  Medline CASGoogle Scholar
• 43 Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152(5), 1139–1145 (2011).
  Medline CASGoogle Scholar
• 44 Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin. Pharmacol. Ther. 92(4), 434–436 (2012).
  Medline CASGoogle Scholar
• 45 Allegaert K, Van Schaik RH, Vermeersch S et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Pediatr. Res. 63(6), 674–679 (2008).
  Medline CASGoogle Scholar
• 46 Babaoglu MO, Yigit S, Aynacioglu AS, Kerb R, Yurdakok M, Bozkurt A. Neonatal jaundice and bilirubin UDP-glucuronosyl transferase 1A1 gene polymorphism in Turkish patients. Basic Clin. Pharmacol. Toxicol. 98(4), 377–380 (2006).
  Medline CASGoogle Scholar
• 47 Kaplan M, Renbaum P, Vreman HJ et al. (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates. Pediatr. Res. 61(6), 727–731 (2007).
  Medline CASGoogle Scholar
• 48 Hansen TVO, Simonsen MK, Nielsen FC, Hundrup YA. Collection of blood, saliva, and buccal cell samples in a pilot study on the danish nurse cohort: comparison of the response rate and quality of genomic DNA. Cancer Epidemiol. Biomarkers Prev. 16(10), 2072–2076 (2007).
  Medline CASGoogle Scholar